Whole recombinant @entity10056 expressing HPV16 L1 antigen is superior in inducing protection against XXXX growth as compared to killed transgenic @entity28010 .

@entity5 @entity10056 @entity19 @entity28010 @entity281 @entity1799 @entity375
The development of an efficient vaccine against high-risk HPV types can reduce the incidence rates of cervical @entity5 by generating anti- @entity5 protective responses. Traditionally, the majority of prophylactic viral vaccines are composed of live, attenuated or inactivated viruses. Among them, the design of an effective and low-cost vaccine is critical. Inactivated vaccines especially heat-killed @entity375 cells have emerged as a promising approach for generating antigen-specific immunotherapy. Recent studies have indicated that @entity375 cell wall components possess adjuvant activities. Moreover, a non-pathogenic protozoan, @entity28010 (L.tar) has attracted a great attention as a live candidate vaccine. In current study, immunological and protective efficacy of whole recombinant killed @entity10056 and @entity28010 expressing @entity1799 L1 capsid protein was evaluated in @entity5 @entity19 model. We found that Pichia-L1, L.tar-L1 and Gardasil groups increase the IgG2a/IgG1 ratio, indicating a relative preference for the induction of Th1 immune responses. Furthermore, subcutaneous injection of killed Pichia-L1 generated the significant L1-specific IFN-y immune response as well as the best protective effects in vaccinated @entity19 as compared to killed L.tar-L1, killed @entity10056 , killed L.tar and PBS groups. Indeed, whole recombinant @entity28010 could not protect @entity19 against C3 @entity5 @entity19 model. These data suggest that Pichia-L1 may be a candidate for the control of @entity281 .
